FORT WORTH, TX, August 2, 2022 (GLOBE NEWSWIRE) – TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) is a clinical stage biopharmaceutical company specializing in the Thin Film Refrigeration (TFF) technology platform for the development and commercialization of innovative pharmaceutical products, today announced that it will release its second quarter 2022 financial results and business review on Thursday. August 11, 2022, at the close of US financial markets.
Management will hold a conference call at 4:30 pm ET to discuss financial results and provide an update on corporate and clinical developments. The presentation will be followed by a Q&A session with investors.
The company will hold a conference call on Thursday, August 11, 2022 at 4:30 pm ET to review clinical, corporate and financial performance. To join the conference, join the webcast or dial one of the following before starting the call:
The call will also be webcast live and can be accessed on TFF Pharmaceuticals’ Website, https://tffpharma.com or directly at https://viavid.webcasts.com/starthere.jsp?ei=1558913&tp_key=43b9453c47. The call will also be webcast live and can be accessed on TFF Pharmaceuticals’ Website, https://tffpharma.com or directly at https://viavid.webcasts.com/starthere.jsp?ei=1558913&tp_key=43b9453c47. Конференция также будет транслироваться в прямом эфире и доступна на веб-сайте TFF Pharmaceuticals https://tffpharma.com или непосредственно на https://viavid.webcasts.com/starthere.jsp?ei=1558913&tp_key=43b9453c47. The conference will also be streamed live and available on the TFF Pharmaceuticals website https://tffpharma.com or directly at https://viavid.webcasts.com/starthere.jsp?ei=1558913&tp_key=43b9453c47.电话会议还将进行网络直播，可以在TFF Pharmaceuticals 的网站https://tffpharma.com 或直接访问https://viavid.webcasts.com/starthere.jsp?ei=1558913&tp_key=43b9453c47 访问。 TFF Pharmaceuticals 的网站https://tffpharma.com 或直接访问https://viavid.webcasts.com/starthere.jsp?ei=1558913&tp_key34=43 Конференц-связь также будет транслироваться в Интернете и доступна на веб-сайте TFF Pharmaceuticals по адресу https://tffpharma.com или напрямую по адресу https://viavid.webcasts.com/starthere.jsp?ei=1558913&tp_key=43b9453c47. The conference call will also be webcast and available on the TFF Pharmaceuticals website at https://tffpharma.com or directly at https://viavid.webcasts.com/starthere.jsp?ei=1558913&tp_key=43b9453c47. Please visit the company’s website at least 15 minutes before your appointment to register, download and install all required audio software. The call will also be played throughout the month in the Investor Calendar section of the company’s website.
About the TFF PHARMACEUTICALS Thin Film Freezing Technology Platform TFF Pharmaceuticals’ patented Thin Film Freezing (TFF) technology allows existing compounds and new chemicals to be converted into dry powder formulations with unique properties and benefits. The film freezing process is a particle engineering process designed to produce dry powder particles with favorable properties for inhalation, parenteral, nasal, oral, topical and ophthalmic routes of administration. This process can be used to develop powders for direct delivery to the desired site, thereby avoiding systemic administration problems and improving bioavailability, faster onset of action, and improving safety and efficacy. The ability to deliver therapy directly to target organs such as the lungs allows TFF powder to be administered at lower doses compared to oral formulations, reducing unnecessary toxicity and side effects. Laboratory data indicate that the aerodynamic properties of thin-film frozen powders can deliver up to 75% of a dose deep into the lungs. Instead of exposure to heat, shear stress, or other forces that can damage more complex therapeutic components such as fragile biologicals, thin-film freezing allows these materials to be converted into dry powders that are easy to store and temperature stable, allowing therapeutics and vaccines to be distributed more globally. . The benefits of thin film freezing can be used to improve traditional delivery or in combination with next generation pharmaceuticals.
ABOUT TFF PHARMACEUTICALS TFF Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that uses patented quick freeze technology to develop and convert drugs into effective dry powder formulations to improve efficacy, safety and stability. The company’s versatile Thin Film Freezing (TFF) technology platform has a wide application and turns any drug, including vaccines, small and large molecules, and biologics, into elegant dry powders that are easy to inhale and better absorbed, so the drug can also be delivered. in the eyes, nose and local skin. TFF has two major clinical drug candidates, voriconazole inhalation powder and tacrolimus inhalation powder, and continues to expand its portfolio to revolutionize global healthcare by collaborating with a wide range of pharmaceutical companies, academic institutions and government partners. The TFF platform is covered by over 120 patents issued or pending in the US and other countries. To learn more about TFF Pharmaceuticals and its candidate products, please visit the company’s website at https://tffpharma.com.
Safe Harbor This press release contains forward-looking statements about TFF Pharmaceuticals, Inc., including its expectations for continued development of tacrolimus and voriconazole inhaled powders, the benefits of the company’s TFF platform, and the company’s plans to add to its existing candidate product line. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. These factors include: (i) the risk that the company will not be able to successfully complete clinical trials or obtain premarket approval for its inhaled tacrolimus, voriconazole powder, or any of its dry powder candidates, (ii) the lack of listing of the drug on the TFF platform has received FDA prior approval or otherwise listing a commercial drug, (iii) the company does not currently have an agreement or understanding with any major pharmaceutical company to develop a drug for inclusion in the TFF platform, (iv) the company will not be able to enter into long-term commercial agreements with any third party; and (v) other risks identified in the “Risk Factors” section of Form 10 of the company’s 2021 Annual Report – K, filed with the SEC on March 24, 2022. TFF Pharmaceuticals cautions readers not to place undue reliance on any or forward-looking statements. TFF Pharmaceuticals assumes and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unforeseen circumstances, except as required by law.
TFF Pharmaceuticals Investor Relations Contact: Corey Davis, PhD LifeSci Advisorsscdavis@lifesciadvisors.com 212-915-2577
TFF Pharmaceuticals Media Contact: Gwendolyn SchankerLifeSci Communications(269) 921-3607gschanker@lifescicomms.com
Post time: Aug-10-2022